(Q38084159)

28 August 2017

title

Novel anti-platelet agents: focus on thrombin receptor antagonists (English)

1 reference

28 August 2017

2

Pierluigi Tricoci

1 reference

28 August 2017

author name string

Flavio de Souza Brito

series ordinal

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

22 February 2013

1 reference

Journal of Cardiovascular Translational Research

28 August 2017

published in

1 reference

28 August 2017

volume

6

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

415-424

1 reference

Aspirin: a historical and contemporary therapeutic overview

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Antiplatelet therapy: controversial aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Mechanisms of thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Platelet thrombin receptor antagonism and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Protease-activated receptors in hemostasis, thrombosis and vascular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Identification of Human Liver Cytochrome P450 Enzymes Involved in the Metabolism of SCH 530348 (Vorapaxar), a Potent Oral Thrombin Protease-Activated Receptor 1 Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Promises of PAR-1 inhibition in acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Antiplatelet therapy: thrombin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

PAR-1 antagonists: current state of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Apixaban with antiplatelet therapy after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Vorapaxar in the secondary prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9454-3

Safety of the Novel Protease-Activated Receptor-1 Antagonist Vorapaxar in Japanese Patients with a History of Ischemic Stroke

21 January 2018

1 reference

12 December 2020

Protease-activated receptors in vascular biology

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

1 reference

12 December 2020

Developing PAR1 antagonists: minding the endothelial gap.

1 reference

12 December 2020

10.1007/S12265-013-9454-3

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1016999795

0 references

1 reference